Clinical Review

Mefenamic acid shows no significant interaction with ciprofol in healthy individuals, which suggests that ciprofol is safe and well tolerated when administered along with mefenamic acid, reports a study.

The risk of herpes zoster (HZ) and HZ-related hospitalization is much higher among patients with liver cirrhosis (LC), especially those who are not currently recommended for HZ vaccination, than the general population, according to a nationwide population-based study in Korea.

Adding subablative stereotactic body radiotherapy (SBRT) concurrently to immune checkpoint inhibitor (ICI) monotherapy does little to improve survival outcomes in patients with advanced solid tumours, as shown in the phase II CHEERS trial.

In the treatment of select patients with rheumatoid arthritis (RA), otilimab is neither better than placebo nor noninferior to sarilumab in terms of the proportion of patients achieving an American College of Rheumatology ≥20 percent response (ACR20), according to the results of the phase III ContRAst 3 study.

Use of a chemometric approach appears helpful in the evaluation of interactions between antiretroviral medications and food, suggests a recent study.

Treatment outcomes with nucleos(t)ide analogues for hepatitis B patients appear to differ by sex, such that men are more likely to have biochemical response and achieve clinical remission than women, a study has shown.

Treatment with dupilumab appears to be safe and effective in the treatment of patients with bullous pemphigoid (BP), yielding significant improvements in symptoms with a favourable safety profile, according to a study.

For patients who undergo adalimumab tapering after achieving remission, factors such as age, race, and duration of disease remission on adalimumab appear to impact the risk of relapse, according to a study.

Treatment with tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for type 2 diabetes, leads to substantial reductions in weight despite an increase in gastrointestinal symptoms, according to the results of a meta-analysis.

In the treatment of patients with 3-vessel coronary artery disease (CAD), fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) does not differ from coronary artery bypass grafting (CABG) in terms of the incidence of the composite of death, myocardial infarction (MI), or stroke, according to 3-year data from the FAME 3* trial.